A Double-Blind, Placebo-Controlled Study of the Aqueous Extract of Echium amoenum for Patients with General Anxiety Disorder

Authors

  • Alireza Malayeri Department of Pharmacology, Jundishapur University of Medical Sciences, Ahwaz, Iran.
  • Amir Siahpoosh Herbal Medicine Research Center, Jundishapur University of Medical Sciences, Ahwaz, Iran.
  • Hamidreza Khalili Department of Pharmacology, Jundishapur University of Medical Sciences, Ahwaz, Iran.
  • Hamidreza Samaee College of Pharmacy, Jundishapur University of Medical Sciences, Ahwaz, Iran.
  • Mehdi sayyah Herbal Medicine Research Center, Jundishapur University of Medical Sciences, Ahwaz, Iran.
Abstract:

    The aim of this study was to assess the efficacy and tolerability of the aqueous extract of Echium amoenum in combination with SSRIs in patients with General Anxiety Disorder (GAD). The study was an 8-week double-blind randomized clinical trial. Thirty-seven adult outpatients who met the DSM-IV-TR criteria for GAD based on the structured clinical interview participated in the trial. In this study, patients were randomly assigned to receive the aqueous extract (500 mg) plus fluoxetine or fluoxetine (20 mg/day) plus placebo. The results showed significant difference between the two groups in the treatment of GAD. Moreover, there was not any significant difference between the two groups in terms of observed side effects. E. amoenum is effective on anxiety disorder, especially in higher dosage, without any serious side effects.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

a double-blind, placebo-controlled study of the aqueous extract of echium amoenum for patients with general anxiety disorder

the aim of this study was to assess the efficacy and tolerability of the aqueous extract of echium amoenum in combination with ssris in patients with general anxiety disorder (gad). the study was an 8-week double-blind randomized clinical trial. thirty-seven adult outpatients who met the dsm-iv-tr criteria for gad based on the structured clinical interview participated in the trial. in this stu...

full text

Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study

Vilazodone is a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist that is approved for treatment of major depressive disorder in adults in the USA and Mexico. The efficacy, safety, and tolerability of vilazodone for generalized anxiety disorder (GAD) were investigated in a clinical trial (NCT01766401 ClinicalTrials.gov). Participants (18-70 years, inclusive) who met D...

full text

Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.

Kava (Piper methysticum) is a plant-based medicine, which has been previously shown to reduce anxiety. To date, however, no placebo-controlled trial assessing kava in the treatment of generalized anxiety disorder (GAD) has been completed. A total of 75 participants with GAD and no comorbid mood disorder were enrolled in a 6-week double-blind trial of an aqueous extract of kava (120/240 mg of ka...

full text

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

OBJECTIVE This study assessed the efficacy of two fixed doses of paroxetine in the treatment of generalized anxiety disorder. METHOD Outpatients (N=566) with generalized anxiety disorder and no other axis I disorder were eligible if they scored >/=20 on the Hamilton Rating Scale for Anxiety (with a score of 2 or higher on the anxious mood and tension items). Following a 1-week placebo run-in ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 11  issue 2

pages  697- 701

publication date 2012-04-10

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023